NEXTBio Capital Management LP Invests $5.19 Million in Compass Pathways PLC Sponsored ADR $CMPS

NEXTBio Capital Management LP purchased a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 752,631 shares of the company’s stock, valued at approximately $5,193,000. Compass Pathways comprises about 3.0% of NEXTBio Capital Management LP’s holdings, making the stock its 13th largest holding. NEXTBio Capital Management LP owned approximately 0.78% of Compass Pathways as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Conservest Capital Advisors Inc. increased its holdings in shares of Compass Pathways by 24.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock worth $175,000 after buying an additional 5,000 shares during the last quarter. Raymond James Financial Inc. increased its holdings in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after buying an additional 6,228 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $41,000. BIT Capital GmbH acquired a new stake in shares of Compass Pathways during the 3rd quarter worth approximately $54,000. Finally, Intellectus Partners LLC increased its holdings in shares of Compass Pathways by 22.0% during the 4th quarter. Intellectus Partners LLC now owns 61,000 shares of the company’s stock worth $421,000 after buying an additional 11,000 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Up 5.9%

Compass Pathways stock opened at $12.08 on Friday. Compass Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $14.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The firm has a 50 day moving average price of $9.59 and a 200 day moving average price of $7.60. The company has a market capitalization of $1.63 billion, a PE ratio of -3.83 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CMPS. Canaccord Genuity Group dropped their target price on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, March 26th. HC Wainwright reiterated a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. UBS Group set a $18.00 target price on shares of Compass Pathways in a report on Thursday, May 7th. Finally, B. Riley Financial began coverage on shares of Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.36.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.